Overview

The National Cancer Institute's Pancreatic Cancer: A Summary of NCI's Portfolio and Highlight of Recent Research Progress provides a retrospective analysis of progress such as trends in numbers of NCI-funded pancreatic cancer research projects, publications, initiatives, and clinical trials. In 2000, the National Cancer Institute (NCI) convened the Pancreatic Cancer Progress Review Group (PRG) to review the pancreatic cancer research field and make recommendations concerning the most urgent needs and promising directions for future NCI investment. The PRG's report, Pancreatic Cancer: An Agenda for Action provided priority recommendations in six major areas: Health of the Field and Overarching Issues; Tumor Biology; Risk, Prevention, Screening, and Diagnosis; Therapy; Health Services Research: Scientific Toolkit. In 2007, a Clinical Trials Planning Meeting on Pancreas Cancer Treatment was convened to discuss the integration of basic and clinical knowledge in design of clinical trials in pancreatic adenocarcinoma. A Consensus Report of the meeting published in November 2009 provided recommendations in the following emphasis areas: New Targets for Drug Development; Utility of Preclinical Models; Future Clinical Trials; Establishment of Biorepositories; Development of Biomarkers. NCI's efforts in pancreatic cancer research have increased our understanding of the biological basis for pancreatic cancer, developed potential means to reduce morbidity and mortality associated with the disease, and expanded pancreatic cancer research capacity. The following or some research highlights in the five key priority areas identified by the PRG: Tumor Biology - Research on the tumor biology of pancreatic cancer has increased understanding of factors critical to key steps in the progression of pancreatic cancers; Risk, Prevention, Screening, and Diagnosis - Results of NCI-sponsored research related to the risk, prevention, screening, and diagnosis of pancreatic cancer have identified potential markers associated with pancreatic cancer risk as well as potential diagnostic markers; Therapy - NCI-sponsored research on therapy for pancreatic cancer has investigated optimal timing, delivery, and drug combinations that may improve the treatment of pancreatic cancer.

Full Product Details

9781478117353

Table of Contents

Reviews

Author Information

Tab Content 6

Customer Reviews

Recent Reviews

Countries Available